Masonic Medical Research Institute will host its first telethon Tuesday, Oct. 6, 2026, streaming live across the institute's ...

PRKAG2 syndrome is an autosomal dominant Atrium Therapeutics has received clearance from the US Food and Drug Administration ...

Atrium Therapeutics, Inc. (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has ...

At the 2026 AVMA Convention, Will P. Rausch, DVM, DACVIM (Cardiology), discussed where NT-proBNP fits in feline cardiomyopathy screening and why the test should be used as part of a broader diagnostic ...

Background C-reactive protein (CRP) is commonly used to assess systemic inflammation, yet its prognostic value in acute ...

Objective Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy characterised by pathological left ...

Clinical genetic testing is now the standard of care for cardiomyopathy, guiding risk stratification, clinical management, and earlier diagnosis in family members. Yet, a large proportion of the ...

Heart disease is often associated with blocked arteries or heart attacks, but not all heart conditions develop the same way.

Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need The collaboration will ...

Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies ...

Advances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but current US population‐based epidemiologic data are ...